Titre :

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

Auteur(s) :

Poynard, Thierry [Auteur]
Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] [IHU ICAN]
Centre de Recherche Saint-Antoine [CRSA]
CHU Pitié-Salpêtrière [AP-HP]
Lacombe, Jean Marc [Auteur]
Sorbonne Université [SU]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Deckmyn, Olivier [Auteur]
BioPredictive [Paris]
Peta, Valentina [Auteur]
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [ICAN]
Centre de Recherche Saint-Antoine [CRSA]
Akhavan, S. [Auteur]
De Ledinghen, Victor [Auteur]
Bordeaux Research In Translational Oncology [Bordeaux] [BaRITOn]
Hôpital Haut-Lévêque [CHU Bordeaux]
Zoulim, Fabien [Auteur]
Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL]
Centre de Recherche en Cancérologie de Lyon [UNICANCER/CRCL]
Samuel, Didier [Auteur]
Hôpital Paul Brousse
Physiopathogénèse et Traitement des Maladies du Foie [HEPAREG]
Mathurin, Philippe [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Ratziu, V. [Auteur]
Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [ICAN]
Centre de Recherche Saint-Antoine [CRSA]
CHU Pitié-Salpêtrière [AP-HP]
Thabut, D. [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Housset, C. [Auteur]
Fontaine, Hélène [Auteur]
Hôpital Cochin [AP-HP]
Pol, S. [Auteur]
Carrat, F. [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]

Titre de la revue :

JHEP Reports Innovation in Hepatology

Nom court de la revue :

JHEP Rep

Numéro :

3

Pagination :

100298

Date de publication :

2021-06-23

ISSN :

2589-5559

Mot(s)-clé(s) en anglais :

FibroTest(TM)
Liver Cancer Risk
AFP
Surveillance
LCR1-LCR2
Multi-analyte blood test
Cirrhosis
Fibrosis progression

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a multianalyte blood test combining proteins involved in liver cell repair (apolipoprotein-A1 and haptoglobin), known hepatocellular carcinoma (HCC) ...
Lire la suite >Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a multianalyte blood test combining proteins involved in liver cell repair (apolipoprotein-A1 and haptoglobin), known hepatocellular carcinoma (HCC) risk factors (sex, age, and gamma-glutamyl transferase), a marker of fibrosis (alpha2-macroglobulin) and alpha-fetoprotein (AFP), a specific marker of HCC. The aim was to externally validate the LCR1-LCR2 in patients with chronic HCV (CHC) treated or not with antivirals. Methods Pre-included patients were from the Hepather cohort, a multicentre prospective study in adult patients with CHC in France. LCR1-LCR2 was assessed retrospectively in patients with the test components and AFP, available at baseline. The co-primary study outcome was the negative predictive value (NPV) of LCR1-LCR2 for the occurrence of HCC at 5 years and for survival without HCC according to the predetermined LCR1-LCR2 cut-offs. The cut-offs were adjusted for risk covariables and for the response to HCV treatment, and were quantified using time-dependent proportional hazards models. Results In total, 4,903 patients, 1,026 (21.9%) with baseline cirrhosis, were included in the study. Patients were followed for a median of 5.7 (IQR 4.2–11.3) years. A total of 3,788/4,903 (77.3%) patients had a sustained virological response. There were 137 cases of HCC at 5 years and 214 at the end of follow-up. HCC occurred at 5 years in 24/3,755 patients with low-risk LCR1-LCR2 compared with 113/1,148 patients with high-risk LCR1-LCR2. The NPV was 99.4% (95% CI 99.1–99.6). Similar findings (hazard ratio, 10.8; 95% CI, 8.1–14.3; p <0.001) were obtained after adjustment for exposure to antivirals, age, sex, geographical origin, HCV genotype 3, alcohol consumption, and type 2 diabetes mellitus. Conclusions The results showed that LCR1-LCR2 can be used to successfully identify patients with HCV at very low risk of HCC at 5 years. Lay summary Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide and the fastest growing cause of cancer death in many countries. We constructed and internally validated a new multianalyte blood test to assess this Liver Cancer Risk (LCR1-LCR2). This study confirmed the performance of LCR1-LCR2 in patients with chronic HCV in the national French cohort Hepather, and its ability to identify patients at a very low risk of HCC at 5 years.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T06:40:22Z
2024-03-01T09:25:25Z